Bulletin
Investor Alert

Regulus Therapeutics Inc.

NAS: RGLS

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Dec 6, 2022, 7:16 p.m.

/zigman2/quotes/202916513/composite

$

1.60

Change

+0.08 +5.26%

Volume

Volume 368

Quotes are delayed by 20 min

/zigman2/quotes/202916513/composite

Today's close

$ 1.74

$ 1.52

Change

-0.22 -12.64%

Day low

Day high

$1.52

$1.73

Open

52 week low

52 week high

$1.33

$4.00

Open

Annual Financials for Regulus Therapeutics Inc.

Fiscal year is January-December. All values USD millions. 20172018201920202021 5-year trend
Sales/Revenue 72,00072,0006.83M10.01M-
Cost of Goods Sold (COGS) incl. D&A ----459,000
COGS excluding D&A -----
Depreciation & Amortization Expense 2.52M2.26M931,000467,000459,000
Depreciation 2.42M2.16M900,000367,000359,000
Amortization of Intangibles 100,000100,00031,000100,000100,000
Gross Income ----(459,000)
20172018201920202021 5-year trend
SG&A Expense 67.68M43.77M22.74M23.69M27.36M
Research & Development 53.19M33.1M11.78M14.9M17.35M
Other SG&A 14.49M10.67M10.96M8.8M-
Other Operating Expense -----
Unusual Expense -800,000---
EBIT after Unusual Expense -(46.76M)---
Non Operating Income/Expense -----
Non-Operating Interest Income 752,000459,000374,000233,000864,000
Equity in Affiliates (Pretax) -----
Interest Expense 2.72M2.34M2.13M1.81M855,000
Gross Interest Expense 2.72M2.34M2.13M1.81M855,000
Interest Capitalized -----
Pretax Income (72.1M)(48.65M)(18.59M)(15.73M)(27.81M)
Income Tax (197,000)62,0001,000-1,000
Income Tax - Current Domestic (142,000)(25,000)(12,000)(12,000)1,000
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic (55,000)87,00013,00012,000-
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (71.91M)(48.71M)(18.59M)(15.73M)(27.81M)
Minority Interest Expense -----
Net Income (71.91M)(48.71M)(18.59M)(15.73M)(27.81M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (71.91M)(48.71M)(18.59M)(15.73M)(27.81M)
Preferred Dividends -----
Net Income Available to Common (71.91M)(48.71M)(18.59M)(15.73M)(27.81M)
EPS (Basic) (115.20)(55.87)(10.77)(4.50)(3.24)
Basic Shares Outstanding 626,923871,8561.73M3.5M8.57M
EPS (Diluted) (115.20)(55.87)(10.77)(4.50)(3.24)
Diluted Shares Outstanding 626,923871,8561.73M3.5M8.57M
EBITDA (67.61M)(43.7M)(15.9M)(13.69M)(27.36M)
Link to MarketWatch's Slice.